Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease

Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease

(2013) Yi-Lin Chiu et al.   INFLAMMATORY BOWEL DISEASES

Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases

(2011) Warren Strober et al.   GASTROENTEROLOGY

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

(2010) Takuo Suzuki et al.   JOURNAL OF IMMUNOLOGY

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-α Human Monoclonal Antibody, in Patients With Psoriatic Arthritis

(2009) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

(2009) Yaowei Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS